(AEVS) Aevis Victoria SA - Ratings and Ratios

Exchange: SW • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: CH0478634105

AEVS: Healthcare, Hospitality, Real Estate, Telemedicine, Ambulance, Radiology, Pharmacy

Aevis Victoria SA is a Swiss-based conglomerate with a diverse portfolio of businesses, primarily focused on the healthcare, hospitality, lifestyle, and infrastructure sectors. The company's operations are organized into distinct segments, including Hospitals, Hospitality, Real Estate, and Others, allowing for a structured approach to managing its various interests. Through these segments, Aevis Victoria SA provides a wide range of services, including telemedicine, ambulance services, and life sciences-related activities, demonstrating its commitment to comprehensive healthcare solutions.

In addition to its core healthcare services, the company also operates a variety of ancillary businesses, such as patient hotels, radiology institutes, pharmacies, and ophthalmology clinics, further expanding its reach within the healthcare sector. Moreover, Aevis Victoria SA offers specialized services like urology centers, health centers, and day clinics, catering to specific medical needs. The company's presence in the lifestyle sector is marked by its operation of golf courses, highlighting its interest in leisure and wellness activities. Other support services, including parking, cleaning, sterilization, and IT-related services, round out the company's portfolio, showcasing its aim to provide integrated solutions.

As a subsidiary of M.R.S.I. Medical Research, Services and Investments S.A., Aevis Victoria SA benefits from its parent company's expertise and resources, potentially enhancing its own capabilities and strategic direction. With its headquarters in Fribourg, Switzerland, the company is well-positioned to serve both local and international markets. Aevis Victoria SA's common stock is listed with the ISIN CH0478634105, and it is classified under the GICS Sub Industry of Health Care Facilities, reflecting its primary focus on healthcare services and infrastructure. The company's web presence can be found at https://www.aevis.com, offering a gateway to its corporate information, services, and initiatives.

Additional Sources for AEVS Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

AEVS Stock Overview

Market Cap in USD 1,377m
Sector Healthcare
Industry Medical Care Facilities
GiC Sub-Industry Health Care Facilities
IPO / Inception

AEVS Stock Ratings

Growth 5y 10.1%
Fundamental -4.57%
Dividend 9.91%
Rel. Strength Industry -482
Analysts -
Fair Price Momentum 13.00 CHF
Fair Price DCF -

AEVS Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y %
Annual Growth 5y -100.00%
Payout Consistency 48.3%

AEVS Growth Ratios

Growth Correlation 3m 23.5%
Growth Correlation 12m -81.9%
Growth Correlation 5y 64.5%
CAGR 5y 1.38%
CAGR/Mean DD 5y 0.09
Sharpe Ratio 12m -0.58
Alpha -24.76
Beta 0.27
Volatility 59.15%
Current Volume 3.5k
Average Volume 20d 6.6k
What is the price of AEVS stocks?
As of January 22, 2025, the stock is trading at CHF 14.00 with a total of 3,519 shares traded.
Over the past week, the price has changed by +5.15%, over one month by +2.14%, over three months by +2.51% and over the past year by -12.80%.
Is Aevis Victoria SA a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Aevis Victoria SA is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -4.57 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AEVS as of January 2025 is 13.00. This means that AEVS is currently overvalued and has a potential downside of -7.14%.
Is AEVS a buy, sell or hold?
Aevis Victoria SA has no consensus analysts rating.
What are the forecast for AEVS stock price target?
According to ValueRays Forecast Model, AEVS Aevis Victoria SA will be worth about 14 in January 2026. The stock is currently trading at 14.00. This means that the stock has a potential upside of +0.29%.
Issuer Forecast Upside
Wallstreet Target Price 15 7.1%
Analysts Target Price - -
ValueRay Target Price 14 0.3%